Search

Search Results

• The analysis of a wide spectrum of activity of Sodium-Glucose co-transporter-2 inhibitors. A literature review

  Magdalena Kozioł, Danuta Krasowska, Marcin Lewicki, Mateusz Pawlicki, Anna Łopuszyńska, Aleksandra Krasa, Ewa Piekarska

  439-449

  2020-08-30
• SGLT2-Inhibitors - significant role in Heart Failure treatment

  Karol Wielgus, Piotr Bator, Maria Pawłowska, Karol Magiera, Krystian Rachwał, Maria Antos, Jan Ramian, Grzegorz Łyko

  49418

  2024-05-22
• Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes

  Marcin Czarkowski, Karolina Raksa, Ewelina Powroźniak, Karol Spozowski

  319-327

  2022-09-01
• Ketoacidosis without significantly hyperglycaemia - is it possible?

  Michał Budzyński, Joanna Pekar, Justyna Magdalena Skolarczyk, Monika Tadla, Katarzyna Skórzyńska-Dziduszko

  201-205

  2017-06-10
• SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology

  Marta Bogowska, Aleksandra Berner, Klaudia Marczyk, Karolina Matyja, Anna Olszewska, Maciej Pękała, Paulina Polak, Monika Polaszek, Karina Stelmaszak, Katarzyna Stencel

  185-199

  2023-10-03
• Sodium-glucose co-transporter 2 inhibitors – a review article

  Marcin Makuch, Marcelina Makuch, Ewa Krzewicka-Romaniuk, Grzegorz Dzida

  42-49

  2019-08-20
• The use of SGLT2 inhibitors in the treatment of cognitive disorders

  Marta Lato, Konrad Iberszer, Maria Litwiniuk, Marcin Zaniuk, Kamil Hurkała, Dominika Antonik, Barbara Denys, Karolina Góra, Wojciech Zdziennicki, Patryk Zimnicki

  27-39

  2023-05-02
• SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review

  Michał Szczepański, Marcin Kuliga, Mateusz Bajak, Julia Słowik, Julia Inglot, Jadwiga Inglot, Dominik Maciej Feret, Daniel Zapasek, Maciej Mamczur, Damian Sowa

  56369

  2024-12-08
• Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus

  Mirella Czapska, Kamila Babkiewicz, Szczepan Pabis, Katarzyna Skórzyńska-Dziduszko

  335-351

  2018-12-14